Stockreport

4DMT Reports First Quarter 2024 Financial Results and Operational Highlights

4D Molecular Therapeutics, Inc.  (FDMT) 
PDF Announced positive interim data from PRISM Phase 2 Dose Expansion cohort evaluating 4D-150 in wet AMD patients with severe disease activity and high treatment burden ena [Read more]